Social and Genetic Factors for Lymphoma Survivors

Recruiting at 437 trial locations

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: ECOG-ACRIN Cancer Research Group

Disqualifiers: Active therapy, Non-English speakers, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 5

2000 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to understand how social and genetic factors affect the health of young adults who have survived Hodgkin or non-Hodgkin lymphoma. Researchers collect blood samples and health information to identify factors that might increase the likelihood of health issues after cancer treatment. This study targets individuals who were between 15-39 years old at diagnosis, have completed their treatment, and are not currently receiving cancer therapy. Participants will complete health questionnaires and provide blood samples multiple times over two years. As an unphased trial, this study offers participants the opportunity to contribute to valuable research that could improve long-term health outcomes for cancer survivors.

Do I have to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. However, you must not be receiving active therapy for Hodgkin or non-Hodgkin lymphoma.

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores how social and genetic factors influence the health outcomes of young cancer survivors, which is a fresh angle compared to standard treatments focusing solely on medical interventions. Unlike typical cancer treatments that may include surgery, chemotherapy, or radiation, this approach uses observational methods like questionnaires and blood samples to gather data. This could lead to insights that help personalize care and improve quality of life for survivors by considering their social environment and genetic makeup.

Who Is on the Research Team?

Bradley J Zebrack

Principal Investigator

ECOG-ACRIN Cancer Research Group

Are You a Good Fit for This Trial?

Inclusion Criteria

The patient must have been in the age range of 15-39 when their initial Hodgkin lymphoma or NHL cancer diagnosis occurred.

Your most recent systemic treatment for your initial diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma must have been within the past 12 months to be eligible.

In order to partake in this study, you must be fluent in English and able to complete the Quality of Life (QOL) forms.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Participants complete questionnaires about health-related quality of life and undergo collection of blood samples

1 visit

1 visit (in-person)

Follow-up

Participants complete questionnaires and provide blood samples at 6, 12, 18, and 24 months to assess quality of life and other health metrics

24 months

4 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• Biospecimen Collection

How Is the Trial Designed?

Group I: Observational (questionnaires, biospecimen collection) Experimental Treatment 3 Interventions

Participants complete questionnaires about health-related quality of life and undergo collection of blood samples at baseline and 6, 12, 18, and 24 months.

Who Is Running the Clinical Trial?

ECOG-ACRIN Cancer Research Group

Lead Sponsor

Trials

122

Recruited

160,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+